Montelukast vs Topiramate: side-by-side comparison
Montelukast (Leukotriene receptor antagonist) and Topiramate (Antiepileptic (sulfamate-substituted monosaccharide)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Montelukast | Topiramate |
|---|---|---|
| Therapeutic class | Leukotriene receptor antagonist | Antiepileptic (sulfamate-substituted monosaccharide) |
| CAS | 158966-92-8 | 97240-79-4 |
| ATC | R03DC03 | N03AX11 |
| Molecular weight | 586.18 g/mol | 339.36 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Montelukast and Topiramate share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Montelukast acts by a different mechanism than Topiramate, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Montelukast: Montelukast selectively blocks the CysLT1 receptor, which mediates the action of leukotrienes C4, D4 and E4 — proinflammatory mediators released by mast cells and eosinophils in the airway. Topiramate: Topiramate is a sulfamate-substituted monosaccharide with multiple mechanisms of action: blockade of voltage-gated sodium channels, enhancement of gamma-aminobutyric acid (GABA) activity at non-benzodiazepine GABA-A rece…
Indications compared
Montelukast: Montelukast is approved in adults and children for the maintenance treatment of asthma, including exercise-induced bronchospasm, and for the treatment of seasonal and perennial allergic rhinitis when conventional therapy… Topiramate: Topiramate is approved in adults and children for the treatment of partial-onset seizures, primary generalised tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome (as adjunctive or monotherapy depe…
Safety profile
Montelukast: Common adverse effects include headache, gastrointestinal symptoms and upper respiratory tract infection. Topiramate: Common adverse effects include paraesthesia, fatigue, dizziness, anorexia and weight loss, and cognitive symptoms (word-finding difficulties, concentration problems).
Frequently asked questions
Is Montelukast better than Topiramate? ▾
Montelukast and Topiramate are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Montelukast and Topiramate be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Montelukast
Products with Topiramate
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.